Role of tipranavir in treatment of patients with multidrug-resistant HIV

References

• World Health OrganizationWorld Health Statistics 2009: Cause of specific mortality and morbidity Available at: http://www.who.int/whosis/whostat/EN_WHS09_Table2.pdfAccessed on Dec 6, 2009
   Google Scholar
• Department of Health and Human Services, Centers for Disease Control and PreventionCases of HIV infection and AIDS in the United States and Dependent Areas, 2007HIV/AIDS surveillance report200719163
   Google Scholar
• WheelerWMahleKBodnarUAntiretroviral drug resistance mutations and subtypes in drug-naïve persons newly diagnosed with HIV-1 infection, United States, Mar 2003–Oct 200614th Conference on Retroviruses and Opportunistic Infections (CROI 2007)2007 Feb 25–28Los Angeles, CA
   Google Scholar
• VianiRPeraltaAAldrovandiGPrevalence of primary HIV drug resistance among recently infected adolescents; a multicenter adolescent trials network study: ATN02913th Conference on Retroviruses and Opportunistic Infections (CROI 2007)2006 Feb 5–8Denver, CO
   Google Scholar
• HuDJDonderoTJRayfieldMAThe emerging genetic diversity of HIV-the importance of global surveillance for diagnostics, research, and preventionJAMA1996275932102168604174
   PubMedGoogle Scholar
• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsDepartment of Health and Human Services20091211161 Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdfAccessed on: Apr 14, 2009
   Google Scholar
• Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected ChildrenGuidelines for the use of antiretroviral agents in pediatric HIV infection20092231139 Available at: http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdfAccessed on Apr 20, 2009
   Google Scholar
• JohnsonVABrun-VézinetFClotetBUpdate of the drug resistance mutations in HIV-1: Dec 2008Top HIV Med200816513814519106428
   PubMedGoogle Scholar
• SchmidtBWalterHMoschikBSimple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistanceAIDS200014121731173810985309
   PubMed Web of Science ®Google Scholar
• MeynardJLVrayMMorand-JoubertLPhenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trialAIDS200216572773611964529
   PubMed Web of Science ®Google Scholar
• VrayMMeynardJLDalbanCPredictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088)Antivir Ther20038542743414640390
   PubMed Web of Science ®Google Scholar
• HalesGBirchCCroweSA randomised trial comparing genotypic and virtual phenotypic interpretation of HIV-drug resistance: The CREST StudyPLoS Clin Trials20061319
   Google Scholar
• RomanelliFPomeroyCHuman immunodeficiency virus drug resistance testing: State of the art in genotypic and phenotypic testing of antiretroviralsPharmacotherapy200020215115710678293
   PubMed Web of Science ®Google Scholar
• ReevesJDPieferAJEmerging drug targets for antiretroviral therapyDrugs200565131747176616114975
   PubMed Web of Science ®Google Scholar
• DomsRWPeiperSCUnwelcomed guests with master keys: How HIV uses chemokine receptors for cellular entryVirology199723521791909281497
   PubMed Web of Science ®Google Scholar
• GulickRMLelezariJGoodrichJMaraviroc for previously treated patients with R5 HIV-1 infectionN Engl J Med200835914142944118832244
   PubMed Web of Science ®Google Scholar
• WoodAArmourDThe discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDSProg Med Chem20054323927115850827
   PubMedGoogle Scholar
• Fda.gov [homepage on Internet]Silver Spring, MDU.S. Food and Drug Administration Available from: http://www.fda.gov/Accessed on Jun 16, 2010
   Google Scholar
• Emea.europa.eu [homepage on the Internet]LondonEuropean Medicines Agencyc1995 [updated 2009 Apr 30]. Available from: http://www.emea.europa.eu/Accessed on May 6, 2009
   Google Scholar
• PfizerAn open label pharmacokinetic, safety and efficacy study of maraviroc in combination with background therapy for the treatment of HIV-1 infected, CCR5ClinicalTrials.gov [Internet]Bethesda, MDNational Library of Medicine (US)c2000 [updated 2009 May 5]. Available from: http://clinicaltrials.gov/ct2/show/NCT00791700: NCT00791700Accessed on May 8, 2009
   Google Scholar
• YoungWMonogram Biosciences introduces new co-receptor tropism assay, profile, availability82007 Available from: http://www.natap.org/2007/HIV/082107_04.htmAccessed on Jun 21, 2009
   Google Scholar
• WildCTShugarsDCGreenwellTKMcDanalCBMatthewsTJPeptides corresponding to a predictive α–helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infectionProc Natl Acad Sci U S A19949121977097747937889
   PubMed Web of Science ®Google Scholar
• LalezariJPHenryKO’HearnMEnfuvirtide, an HIV-1 fusion inhibitor for drug-resistant HIV infection in North and South AmericaN Engl J Med2003348222175218512637625
   PubMed Web of Science ®Google Scholar
• LazzarinAClotetBCooperDEfficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and AustraliaN Engl J Med2003348222186219512773645
   PubMed Web of Science ®Google Scholar
• NelsonMArastéhKClotetBDurable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1 infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsJ Acquir Immune Defic Syndr200540440441216280694
   PubMed Web of Science ®Google Scholar
• XuLPozniakAWildfireAEmergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41Antimicrob Agents Chemother20054931113111915728911
   PubMed Web of Science ®Google Scholar
• SuCMelbyTDeMasiRRavindranPHeilek-SnyderGGenotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitroJ Clin Virol200636424925716765082
   PubMed Web of Science ®Google Scholar
• TrottierBWalmsleySReynesJSafety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1infected adults over 48 weeksJ Acquir Immune Defic Syndr200540441342116280695
   PubMed Web of Science ®Google Scholar
• MitsuyaHWeinholdKJFurmanPA3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- associated virus in vitroProc Natl Acad Sci U S A19858220709671002413459
   PubMed Web of Science ®Google Scholar
• TramontanoEPirasGMellorsJWPutzoluMBazmiHZLa CollaPBiochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformateBiochem Pharmacol19985612158315899973178
   PubMed Web of Science ®Google Scholar
• RahimSFredrickLMda SilvaBABernsteinBKingMSGeographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western EuropeHIV Clin Trials20091029410319487179
   PubMed Web of Science ®Google Scholar
• MerluzziVJHargraveKDLabadiaMInhibition of replication by a non-nucleoside reverse transcriptase inhibitorScience19902504986141114131701568
   PubMed Web of Science ®Google Scholar
• RenJStammersDKStructural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptaseVirus Res200813415717018313784
   PubMed Web of Science ®Google Scholar
• NadlerJPBergerDSBlickGEfficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: Primary 24-week analysisAIDS200721611017148962
   PubMed Web of Science ®Google Scholar
• MadrugaJVCahnPGrinsztejnBEfficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trialLancet20073709581293817617270
   PubMed Web of Science ®Google Scholar
• CohenCJBergerDSBlickGEfficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trialAIDS200923342343119114852
   PubMed Web of Science ®Google Scholar
• LazzarinACampbellTClotetBEfficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomized, double-blind, placebocontrolled trialLancet20073709581394817617271
   PubMed Web of Science ®Google Scholar
• LatailladeMKozalMJThe hunt for HIV-1 integrase inhibitorsAIDS Patient Care STDS200620748950116839248
   PubMed Web of Science ®Google Scholar
• JegedeOBabuJdi SantoRHIV type 1 integrase inhibitors: From basic research to clinical implicationsAIDS Rev200810317218918820719
   PubMed Web of Science ®Google Scholar
• SteigbigelRTCooperDAKumarPNRaltegravir with optimized background therapy for resistant HIV-1 infectionN Engl J Med2008359433935418650512
   PubMed Web of Science ®Google Scholar
• CooperDASteigbigelRTGatellJMSubgroup and resistance analyses of raltegravir for resistant HIV-1 infectionN Engl J Med2008359435536518650513
   PubMed Web of Science ®Google Scholar
• SiskindRClinicalTrials.gov [Internet]Safety and effectiveness of raltegravir (MK-0518) in treatment-experienced, HIV-infected children and adolescentsBethesda, MDNational Library of Medicine (US)c2000 [updated March 9, 2009]. Available from: http://clinicaltrials.gov/ct2/show/NCT00485264Accessed on May 6, 2009
   Google Scholar
• RobertsNAMartinJAKinchingtonDRational design of peptide-based HIV proteinase inhibitorsScience199024849533583612183354
   PubMed Web of Science ®Google Scholar
• PetersonMLWangYvan der LaanMJVirologic efficacy of boosted double versus boosted single protease inhibitor therapyAIDS200721121547155417630549
   PubMed Web of Science ®Google Scholar
• GallantJEProtease-inhibitor boosting in the treatment-experienced patientsAIDS Rev20046422623315700621
   PubMed Web of Science ®Google Scholar
• SensionMPilieroPJRitonavir-boosted protease inhibitors: Impact of ritonavir on toxicities in treatment-experienced patientsJ Assoc Nurses AIDS Care2007181364717338984
   PubMed Web of Science ®Google Scholar
• ChenZLiYSchockHBHallDChenEKuoLCThree-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trialsJ Biol Chem19952703721433214367665551
   PubMed Web of Science ®Google Scholar
• ClotetBBellosNMolinaJEfficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trialsLancet200736995681169117817416261
   PubMed Web of Science ®Google Scholar
• de MeyerSVangeneugdenTvan BaelenBResistance profile of darunavir: Combined 24-week results from the POWER trialsAIDS Res Hum Retroviruses200824337938818327986
   PubMed Web of Science ®Google Scholar
• KingNMPrabu-JeyabalanMNalivaikaEAWigerinckPde BéthuneMPSchifferCAStructural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitorJ Virol20047821120121202115479840
   PubMed Web of Science ®Google Scholar
• TieYBorossPIWangYFHigh resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strainsJ Mol Biol2004338234135215066436
   PubMed Web of Science ®Google Scholar
• Prestiza^® healthcare professionals full prescribing information32009 Available from: http://www.prezista.com/prezista/hcp/full_prescribing_information.htmlAccessed on Jul 31, 2009
   Google Scholar
• MadrugaJVBergerDMcMurchieMEfficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trialLancet20073709581495817617272
   PubMed Web of Science ®Google Scholar
• TurnerSRStrobachJWTommasiRATipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide classJ Med Chem19984118346734769719600
   PubMed Web of Science ®Google Scholar
• KohYDasDAmanoMNon-peptidyl small molecule protease dimerization inhibitors (PDIs): Molecular and structural ananlysis of their HIV-1 inhibition and interactions with protease monomer subunit15th Conference on Retroviruses and Opportunistic Infections (CROI 2008)2008 Feb 3–6Boston, MA
   Google Scholar
• PoppeSMSladeDEChongKTAntiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitorAntimicrob Agents Chemother1997415105810639145869
   PubMed Web of Science ®Google Scholar
• MazzaFTronconiEValeroAThe non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell lineJ Eukaryot Microbiol200653Suppl 1S144S14617169036
   PubMedGoogle Scholar
• SquiresKMcCallisterSLazzarinATipranavir/ritonavir (TPV/r) demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: Correlation of baseline genotype and antiviral activity in BI 1182.52The 2nd IAS conference on HIV pathogenesis and treatment (IAS 2003)2003 Jul 13–16Paris, France
   Google Scholar
• MacArthurRDRichmondDCraneLRTipranavir/ritonavir: Derivation of doses that achieve effective plasma concentrations above the IC50 for multiple PI-resistantHIV-1 viruses8th International Congress on Drug Therapy in HIV Infection (HIV 2006)2006 Nov 12–16Glasgow, Scotland
   Google Scholar
• ParkinNChappeyCProtease mutations associated with higher or lower than expected tipranavir (TPV) susceptibility based on the TPV mutation score13th Conference on Retroviruses and Opportunistic Infections (CROI 2006)2006 Feb 5Denver, CO
   Google Scholar
• YeniPMacGregorTGatheJCorrelation of viral load reduction and plasma levels in multiple protease inhibitor experienced patients taking tipranavir/ritonavir in a Phase IIB trial: BI 1182.5210th Conference on Retroviruses and Opportunistic Infections (CROI 2003)2003 Feb 10–14Boston, MA
   Google Scholar
• MorelloJGarcía-GascóPRodríguez-NovoaSUsefulness of the genotypic inhibitory quotient in HIV patients treated with tipranavirThe 4th IAS conference on HIV pathogenesis and treatment (IAS 2007)2007 Jul 22–25Sydney, Australia
   Google Scholar
• BonoraSde RequenaDGCalcagnoATipranavir (TPV) genotypic inhibitory quotient (gIQ) predicts early virological response to TPV-based salvage regimens13th Conference on Retroviruses and Opportunistic Infections (CROI 2006)2006 Feb 5–8Denver, CO
   Google Scholar
• MorseGDCatanzaroLMAcostaEPClinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimize pharmacotherapyLancet200664215225
   Web of Science ®Google Scholar
• HicksCBCahnPCooperDADurable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trialsLancet2006368953446647516890833
   PubMed Web of Science ®Google Scholar
• de RequenaDGBonoraSCalcagnoATipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimensAntimicrob Agents Chemother20085231066107118160524
   PubMed Web of Science ®Google Scholar
• SalazarJCCahnPNegraMDPredictors of response to TPV/r in pediatric patients: Results of BI1182.14/PACTG105114th Conference on Retroviruses and Opportunistic Infections (CROI 2007)2006 Feb 25–28Los Angeles, CA
   Google Scholar
• MayersDLKohlbrennerVMDohnanyilCThe inhibitory quotient (IQ) of tipranavir/ritonavir (tpv/r) in triple class experienced HIV+ patients: Results from bi 1182.52The 2nd IAS conference on HIV pathogenesis and treatment (IAS 2003)2003 Jul 13–16Paris, France
   Google Scholar
• ValdezHMcCallisterSKohlbrennerVMayersDTipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400 copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced HIV+ patientsThe 3rd IAS conference on HIV pathogenesis and treatment (IAS 2005)2005 Jul 24–27Rio de Janeiro, Brazil
   Google Scholar
• NaegerLKZhengJJStrubleKAVirologic response to tipranavir based on plasma concentration (Cmin) and baseline resistance parameters13th Conference on Retroviruses and Opportunistic Infections (CROI 2006)2006 Feb 5–8Denver, CO
   Google Scholar
• FlexnerCBateGKirkpatrickPTipranavirNat Rev Drug Discov200541295595616370086
   PubMed Web of Science ®Google Scholar
• McCallisterSValdezHCurryKA 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patientsJ Acquir Immune Defic Syndr200435437638215097154
   PubMed Web of Science ®Google Scholar
• VourvahisMDumondJPattersonKEffects of tipranavir/ritonavir (TPV/r) on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein (P-gp): Implications for drug interactions14th Conference on Retroviruses and Opportunistic Infections (CROI 2007)2007 Feb 25–28Los Angeles, CA
   Google Scholar
• BaldwinJRBoronMTWangJSchneckDWHopkinsNKEffects of food and antacid on bioavailability of the protease inhibitor PNU- 140690 in healthy volunteers5th Conference on Retroviruses and Opportunistic Infections (CROI 1998)1998 Feb 1–5Chicago, IL
   Google Scholar
• SaboJPHuettnerSMacGregorTRWruckJEvaluation of the bioavailability of tipranavir/ritonavir (TPV/r) 500 mg/200 mg oral solution (OS): Comparison to TPV capsules and the influence of food intake in healthy volunteers6th International Workshop on Clinical Pharmacology of HIV Therapy (NATP 2005)2005 Apr 28–30Québec City, Canada
   Google Scholar
• GatheJCooperDAFarthingCEfficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trialClin Infect Dis200643101337134617051503
   PubMed Web of Science ®Google Scholar
• CahnPVillacianJLazzarinARitonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial2006431013471356
   Google Scholar
• SalazarJCCahnPYogevREfficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1 infected children and adolescentsAIDS200822141789179818753862
   PubMed Web of Science ®Google Scholar
• SalazarJCCahnPGiaquintoCYogevRMiklJEfficacy and safety profile of APTIVUS oral solution or capsules co-administered with low dose ritonavir (APTIVUS/r) in treatment experienced children and teenagers after two years of treatment (Phase I/IIa study)XVII International AIDS Conference (AIDS 2008)2008 Aug 3–8Mexico City, Mexico
   Google Scholar
• Division of AIDS table for grading the severity of adult and pediatric adverse events version 1.0122004 Available from: http://www3.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/PDF/DAIDSAEGradingTable.pdfAccessed on May 5, 2009
   Google Scholar
• HuangICWuAWFinnernHWThijsHGatheJCFaircloughDLHealth-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimensAntivir Ther2008131152518389895
   PubMed Web of Science ®Google Scholar